

Q² 12. (amended) The method of claim 1, wherein the step of providing isolated dendritic cells further comprises treating the isolated transfected dendritic cells with isolated activated platelets or membrane microparticles thereof which contain P selectin.

13. (amended) The method of claim 1, wherein the isolated dendritic cells are administered intravenously.

Q³ 19. (amended) The method of claim 14, wherein the step of providing isolated dendritic cells further comprises culturing the isolated dendritic cells to expand the isolated dendritic cells.

20. (amended) The method of claim 14, wherein the isolated platelet modified dendritic cells are administered intravenously.

Q⁴ 30. (amended) The composition of claim 28, wherein the amount of the selectin polypeptide expressed on the cell surface is greater than the naturally occurring amount of the selectin expressed on the cell surface *in vitro* and is sufficient to target the genetically modified dendritic cells to peripheral lymph nodes.

Q⁵ 37. (amended) A vaccine composition comprising the composition of claim 28 and an antigen.

Q⁶ 48. (amended) A method for stimulating an immune response to an antigen in a subject comprising
administering to the subject the vaccine composition of claim 37.